Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 11/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 10/20 | 1.00 |
| ▸ | TUBB | P07437 | 10/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 10/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 10/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 10/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 10/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 10/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 10/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 10/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 10/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 10/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 10/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 10/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 10/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 0.60 |
| ▸ | CNR2 | P34972 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | ESR1 | P03372 | 3/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7786558 | 0.91 | TUBB1 (0.83) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6425076 | 0.90 | TUBB4A (0.82) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6425281 | 0.90 | TUBB4A (0.81) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6060505 | 0.90 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6425079 | 0.89 | TUBB4A (0.80) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5027076 | 0.88 | TUBB1 (0.78) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5027097 | 0.88 | TUBB4A (0.78) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6426146 | 0.88 | TUBB4A (0.78) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5027082 | 0.87 | TUBB4A (0.77) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5026252 | 0.87 | CNR1 (0.78) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859615-B2 | Compounds, compositions and methods for reducing toxicity and treating or preventing diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-14 | — | — | US | claimed |
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-12-22 | — | — | US | claimed |
| EP-2331093-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | The Trustees of Columbia University in the City of New York (US) | 2011-06-15 | — | — | EP | claimed |
| US-20110124690-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-05-26 | — | — | US | claimed |
| WO-2010025272-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-03-04 | — | — | WO | claimed |
| WO-2009105123-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-08-27 | — | — | WO | claimed |
| WO-2008103916-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER | THE TRUSTEES OF COLUMBIA UNIVERISTY IN THE CITY OF NEW YORK (US) | 2008-08-28 | — | — | WO | claimed |
| US-20050130221-A1 | Synthesis for the preparation of compounds for screening as potential tubulin binding agents | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2005-06-16 | — | — | US | claimed |
| US-6350777-B2 | METHOXY/ETHOXY SUBSTITUTED 3-AROYL-2-ARYLBENZO(B)THIOPHENES AND BENZO(B)THIOPHENE ANALOGUES; ANTITUMOR AGENTS; CYTOTOXICITY | BAYLOR UNIVERSITY | 2002-02-26 | — | — | US | claimed |
| EP-0984954-A4 | ANTI-MITOTIC AGENTS WHICH INHIBIT TUBULIN POLYMERIZATION | UNIV BAYLOR (US) | 2002-01-16 | — | — | EP | claimed |
| US-20010034454-A1 | Description anti-mitotic agents which inhibit tubulin polymerization | BYLOR UNIVERSITY AND ARIZONA DESEASE CONTROL RESEARCH COMMISSION | 2001-10-25 | — | — | US | claimed |
| EP-0984954-A1 | ANTI-MITOTIC AGENTS WHICH INHIBIT TUBULIN POLYMERIZATION | BAYLOR UNIVERSITY (US) | 2000-03-15 | — | — | EP | claimed |
| US-5886025-A | METHOXY AND ETHOXY SUBSTITUTED 3-AROYL-2-ARYLBENZO(B)THIOPHENES AND BENZO(B)THIOPHENE ANALOGUES | BAYLOR UNIVERSITY (US) | 1999-03-23 | — | — | US | claimed |
| WO-1998039323-A1 | ANTI-MITOTIC AGENTS WHICH INHIBIT TUBULIN POLYMERIZATION | BAYLOR UNIVERSITY (US) | 1998-09-11 | — | — | WO | claimed |
| US-8859615-B2 | Compounds, compositions and methods for reducing toxicity and treating or preventing diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-14 | — | — | US | disclosed |
| EP-1214298-B1 | INDOLE-CONTAINING AND COMBRETASTATIN-RELATED ANTI-MITOTIC AND ANTI-TUBULIN POLYMERIZATION AGENTS | UNIV BAYLOR (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-12-22 | — | — | US | disclosed |
| EP-0984954-A1 | ANTI-MITOTIC AGENTS WHICH INHIBIT TUBULIN POLYMERIZATION | BAYLOR UNIVERSITY (US) | 2000-03-15 | — | — | EP | disclosed |
| US-5886025-A | METHOXY AND ETHOXY SUBSTITUTED 3-AROYL-2-ARYLBENZO(B)THIOPHENES AND BENZO(B)THIOPHENE ANALOGUES | BAYLOR UNIVERSITY (US) | 1999-03-23 | — | — | US | disclosed |
| WO-1998039323-A1 | ANTI-MITOTIC AGENTS WHICH INHIBIT TUBULIN POLYMERIZATION | BAYLOR UNIVERSITY (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | TUBA1C, TUBB1, TOP1 | TUBB1 2/4885TUBB4A 20/4885TUBB 7/4885 |
| US-20010034454-A1 | Description anti-mitotic agents which inhibit tubulin polymerization | TUBB, TUBB1, TUBB3 | TUBB1 2/4885TUBB4A 4/4885TUBB 1/4885 |
| US-20050130221-A1 | Synthesis for the preparation of compounds for screening as potential tubulin binding agents | TUBB, TUBB3, TUBB1 | TUBB1 3/4885TUBB4A 7/4885TUBB 1/4885 |
| US-20110124690-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER | BDNF, NGF, NTRK2 | TUBB1 7/4885TUBB4A 19/4885TUBB 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.